-
British Museum bans photos of Bayeux Tapestry as crowds linger
-
US networks halt Trump coverage over White House ban
-
COP31 host says AI climate footprint to be a summit priority
-
French singer accuses Miley Cyrus of plagiarism
-
Berlin's far-left vote winners reject anti-semitism charges
-
EU fines Google 403 mn euros for location data breach
-
Mancini eager for 'new adventure' on Italy return
-
'Best is yet to come,' says De la Fuente after Spain extension
-
Mbappe says having Zidane as France coach 'like a film'
-
Why diesel prices are rising more than crude oil
-
Palmer, Rice out of England Nations League squad
-
COP31 host says AI's climate footprint to be a summit priority
-
German auto workers stage mass protests in bid to save jobs
-
Renewables hit record in 2025, but world must move faster: report
-
Embattled Merz vows to keep ruling for 'democratic future' of Germany
-
US media outlets to sue Trump administration after White House ban
-
Merz vows to keep ruling coalition together for 'democratic future' of Germany
-
Global stocks rally on lower oil prices, US-China hopes
-
Spain coach De la Fuente gets new deal after World Cup success
-
EU proposes energy rating for data centres
-
Pressure grows on Germany's Merz after election defeats
-
Schoolgirl Yu scorches to second gold as doping case rocks Games
-
China's Zhang beats Japan rivals to Asian Games gymnastics gold
-
Putin's party secures record score in Russia election
-
Samlingen Haupt: Vad pengar avslöjar om oss människor
-
Haupt Koleksiyonu: Paranın Biz İnsanlar Hakkında Anlattıkları
-
Tens of thousands of German auto workers protest to save jobs
-
Spanish PM says unregulated AI could be 'devastating'
-
हॉप्त् कलेक्शन: पैसा हमारे बारे में एक इंसान के रूप में क्या प्रकट करता है
-
Yu, 13, smashes record again with second Asian Games gold
-
Συλλογή Haupt: Τι αποκαλύπτει το χρήμα για εμάς τους ανθρώπους
-
Switzerland to play without Xhaka over fake Covid certificate
-
TradersYard Shifts Focus to Futures Trading
-
From Korean Chipmakers to Leveraged Semiconductor ETFs: STARTRADER Launches 49 New 24/7 Stock and ETF CFDs
-
ハウプト・コレクション:お金が人間について明かすこと
-
Thai badminton player first doping case at Asian Games: testers
-
하우프트 컬렉션: 돈이 우리 인간에 대해 드러내는 것
-
Колекція Гаупта: Що гроші розповідають про нас, людей
-
Indonesia doing 'everything' but struggling to curb fires
-
German far-right AfD poll winner says Merz 'twilight' has begun
-
Sbírka Haupt: Co o nás lidech prozrazují peníze
-
Flights scrapped, evacuations urged as Typhoon Dujuan nears Japan
-
North and South Korea fight out draw in niggly Asian Games clash
-
China confirms Xi to visit US this week for Trump talks
-
Officials say man shot, wounded by ICE agent in Texas
-
مجموعة هاوبت: ما يكشفه المال عنا نحن البشر
-
豪普特收藏:金錢如何揭露人類的本質
-
Colecția Haupt: Ce ne dezvăluie banii despre noi, oamenii
-
Kolekcja Haupta: Co pieniądze mówią o nas, ludziach
-
Sisters of jailed Pakistan ex-PM Imran Khan arrested
Chronic drug shortages frustrate EU pharmacists, patients
At a drug wholesaler warehouse in Belgium, shelves are emptier than they used to be.
Like other EU nations, Belgium has increasingly experienced medicine shortages that vex pharmacists, exasperate patients and risk overloading public health services.
"There are often several dozen medications that are in short supply simultaneously, which makes our lives very difficult," said Didier Ronsyn, a Brussels pharmacist.
An EU audit last month found shortages were a "chronic headache" across the bloc.
Its 27 states reported running critically short of 136 drugs, including antibiotics and medicines used to treat heart attacks, between 2022 and 2024, the European Court of Auditors (ECA) said.
Belgium reported the most cases, with more than a dozen critical instances -- meaning no alternatives are available -- notified to the European Medicines Agency (EMA) in 2024 only.
The cause partially lies in supply chain snags and Europe's over-reliance on Asia for key drug components, the ECA said.
Cheaper prices mean that Asian producers now supply the EU with 70 percent of the active pharmaceutical ingredients it needs, according to a study cited in the ECA report.
The dependency is particularly acute for painkillers, like paracetamol or ibuprofen, and drugs that ran critically low in recent years, including some antibiotics and salbutamol, an asthma drug sold under the brand name Ventolin.
Yet, EU internal market inefficiencies are also to blame.
- 'Colossal workload' -
Drug prices differ within the bloc as national authorities negotiate individually with producers, explained Olivier Delaere, CEO of Febelco, a wholesale distributor that serves about 40 percent of Belgian pharmacies.
As a consequence, manufacturers tend to deliver more to countries that pay more, and just enough to those who drove a harder bargain -- to avoid drugs being re-exported for profit, he said.
Additionally, the ECA said that most medicines are still authorised at national level and packages differ significantly among countries, which makes internal EU trade "more costly and complex".
This causes so-called "local shortages", when a product is not available in one EU country but can be found just across the border in another member state, said Delaere of Febelco.
"It's a growing problem," he said, as a massive automated dispenser stacked with medicine boxes filled green baskets -- each corresponding to a pharmacist's order -- on a conveyor belt in the warehouse behind him.
Some 70 percent of the about one million client calls the firm receives a year "are focused solely on medicine shortages", Delaere said. "It is an absolutely colossal workload and energy drain."
- 'Complicated', for now -
In 2024, EU pharmacists spent on average 11 hours per week managing shortages, according to PGEU, a pharmacists' trade group.
Ronsyn said he often spends an hour a day "making phone calls, checking information, sending patients away, or calling them back to tell them their medication has arrived or in certain cases, that it hasn't" -- something that did not happen in the past.
"It's also tough for the patient, who might panic a little when they don't get their medication on time," he said.
Brussels has been scrambling to find solutions.
In March, the European Commission proposed a "critical medicines act" aimed at boosting manufacturing in the EU by providing incentives and urging member states to move away from price as the key criterion for awarding procurement contracts.
It was followed in July by a "stockpiling strategy" to coordinate stocks and ensure medicines and other goods are available in case of crisis.
A commission spokeswoman said Brussels was confident that these and other recently introduced proposals "will make a substantial difference" and "significantly help tackling the problem".
The bills are currently being negotiated with the European Parliament and member states, a sometimes lengthy process.
"They are trying to find solutions, but it is always very slow," said Ronsyn, whose pharmacy overlooks the commission offices. "We will probably get there someday, but for now it's complicated."
R.Flueckiger--VB